Skip to main navigation menu Skip to main content Skip to site footer
FrancoAngeli Journals

Saggi

No. 129 (2024)

The Impact of Asthma on Healthcare and Management Costs: A Data-Driven Approach

DOI
https://doi.org/10.3280/mesa2024-129oa19007
Submitted
dicembre 10, 2024
Published
2025-02-07

Abstract

Background. Asthma is a chronic disease with a large global prevalence, leading to significant economic and social costs.
Objective. The aim of this study is to estimate the direct costs associated with asthmatic patients, focusing on potential differences in resource utilization between patients with severe and non-severe asthma.
Methods. A data-driven approach was adopted to perform an economic-quantitative analysis of administrative data from Azienda Sanitaria Locale n. 4 (Local Health Authority) in the Liguria Region. After identifying a cohort of asthmatic patients and distinguishing those with severe asthma, costs related to hospitalizations, diagnostic tests, and pharmaceutical expenditures were calculated, taking into account disease severity.
Results. The analysis was conducted on a sample of over 7,000 patients, 11% of whom were diagnosed with severe asthma. On average, the annual direct costs per patient amount to €1,800, with pharmaceutical expenses accounting for 52% of the total. Each year, patients with severe asthma cost the Italian National Health Service (NHS) nearly €1,000 more than patients with mild asthma (€2,644 vs. €1,689, p < 0.001). This difference is primarily attributable to the consumption of drugs for obstructive respiratory syndromes.
Conclusion. The severity of asthma is a strong predictive factor for the direct costs associated with the disease. The
main driver of the higher costs is the more intensive pharmacological treatment required to control symptoms and prevent exacerbations.

References

  1. Accordini, S., Corsico, A., Cerveri, I., Gislason, D., Gulsvik, A., Janson, C., Jarvis, D., Marcon, A., Pin, I., Vermeire, P., Almar, E., Bugiani, M., Cazzoletti, L., Duran-Tauleria, E., Jõgi, R., Marinoni, A., Martínez-Moratalla, J., Leynaert, B., De Marco, R., ... Wjst, M. (2008). The socio-economic burden of asthma is substantial in Europe. Allergy: European Journal of Allergy and Clinical Immunology, 63(1), 116-124. DOI: 10.1111/j.1398-9995.2007.01523.x.
  2. Accordini, S., Corsico, A. G., Braggion, M., Gerbase, M. W., Gislason, D., Gulsvik, A., Heinrich, J., Janson, C., Jarvis, D., Jõgi, R., Pin, I., Schoefer, Y., Bugiani, M., Cazzoletti, L., Cerveri, I., Marcon, A., & De Marco, R. (2013). The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults. International Archives of Allergy and Immunology, 160(1), 93-101. DOI: 10.1159/000338998.
  3. Allegra, L., Cremonesi, G., Girbino, G., Ingrassia, E., Marsico, S., Nicolini, G., & Terzano, C. (2012). Real-life prospective study on asthma control in Italy: Cross-sectional phase results. Respiratory Medicine, 106(2), 205-214. DOI: 10.1016/j.rmed.2011.10.001.
  4. Antonicelli, L., Bucca, C., Neri, M., de Benedetto, F., Sabbatani, P., Bonifazi, F., Eichler, H. G., Zhang, Q., & Yin, D. D. (2004). Asthma severity and medical resource utilisation. European Respiratory Journal, 23(5), 723-729. DOI: 10.1183/09031936.04.00004904.
  5. Bahadori, K., Doyle-Waters, M. M., Marra, C., Lynd, L., Alasaly, K., Swiston, J., & FitzGerald, J. M. (2009). Economic burden of asthma: A systematic review. In BMC Pulmonary Medicine (Vol. 9). DOI: 10.1186/1471-2466-9-24.
  6. Bavbek, S., Malhan, S., Mungan, D., Misirligil, Z., Erdinc, M., Gemicioglu, B., Kivilcim Oguzulgen, I., Oksuz, E., Yildiz, F., & Yorgancioglu, A. (2021). Economic burden of severe asthma in turkey: A cost of illness study from payer perspective. European Annals of Allergy and Clinical Immunology, 53(3), 128-137. DOI: 10.23822/EURANNACI.1764-1489.149.
  7. Bilò, M. B., Antonicelli, L., Carone, M., De Michele, F., Menzella, F., Musarra, A., Tognella, S., Vaghi, A., & Micheletto, C. (2021). Severe asthma management in the era of biologics: Insights of the italian registry on severe asthma (irsa). European Annals of Allergy and Clinical Immunology, 53(3): 103-114. DOI: 10.23822/EurAnnACI.1764-1489.196.
  8. Bousquet, J., Bousquet, P. J., Godard, P., & Daures, J.-P. (2005). The public health implications of asthma. In Bulletin of the World Health Organization (Vol. 83, Issue 7). -- www.who.int/.
  9. Canonica, G. W., Colombo, G. L., Bruno, G. M., Di Matteo, S., Martinotti, C., Blasi, F., Bucca, C., Crimi, N., Paggiaro, P., Pelaia, G., Passalaqua, G., Senna, G., Heffler, E., Stefano, A., Diego, B., Sarah, B., Gianna, C., Marco, C., Giselda, C., ... Massimo, T. (2019). Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organization Journal, 12(1). DOI: 10.1016/j.waojou.2018.12.001.
  10. Conover, W. J. (1980). Practical Nonparametric Statistics (3rd edition, Ed.). John Wiley & Sons. -- http://www.amazon.com/Practical-Nonparametric-Statistics-Series-Probability/dp/0471160687.
  11. Costa, E., Caetano, R., Werneck, G. L., Bregman, M., Araújo, D. V., & Rufino, R. (2018). Estimated cost of asthma in outpatient treatment: A realworld study. Revista de Saude Publica, 52. DOI: 10.11606/S1518-8787.2018052000153.
  12. Dal Negro, R. W., Distante, C., Bonadiman, L., Turco, P., & Iannazzo, S. (2016). Cost of persistent asthma in Italy. Multidisciplinary Respiratory Medicine, 11(1). DOI: 10.1186/s40248-016-0080-1.
  13. Dal Negro, R. W., Micheletto, C., Tosatto, R., Dionisi, M., Turco, P., & Donner, C. F. (2007). Costs of asthma in Italy: Results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study. Respiratory Medicine, 101(12), 2511-2519. DOI: 10.1016/j.rmed.2007.07.011.
  14. De Marco, R., Bugiani, M., Cazzoletti, L., Carosso, A., Accordini, S., Buriani, O., Carrozzi, L., Dallari, R., Giammanco, G., Ginesu, F., Marinoni, A., Lo Cascio, V., Poli, A., Struzzo, P., & Janson, C. (2003). The control of asthma in Italy. A multicentre descriptive study on young adults with doctor diagnosed current asthma. Allergy: European Journal of Allergy and Clinical Immunology, 58(3), 221-228. DOI: 10.1034/j.1398-9995.2003.00059.x.
  15. Demo – Statistiche demografiche. (n.d.). Retrieved October 20, 2023, -- from https://demo.istat.it/.
  16. Doz, M., Chouaid, C., Com-Ruelle, L., Calvo, E., Brosa, M., Robert, J., Decuypère, L., Pribil, C., Huerta, A., & Detournay, B. (2013). The association between asthma control, health care costs, and quality of life in France and Spain. BMC Pulmonary Medicine, 13(1). DOI: 10.1186/1471-2466-13-15.
  17. Global Initiative for Asthma (GINA). (2023). Global Strategy for Asthma Management and Prevention.
  18. Mann, H. B., & Whitney, D. R. (1947). On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other, 18(1): 50-60. DOI: 10.1214/Aoms/1177730491.
  19. McCracken, J. L., Veeranki, S. P., Ameredes, B. T., & Calhoun, W. J. (2017). Diagnosis and management of asthma in adults a review. In JAMA – Journal of the American Medical Association, 318(3): 279-290). American Medical Association. DOI: 10.1001/jama.2017.8372.
  20. Nguyen, H. V., Nadkarni, N. V., Sankari, U., Mital, S., Lye, W. K., & Tan, N. C. (2017). Association between asthma control and asthma cost: Results from a longitudinal study in a primary care setting. Respirology, 22(3): 454-459. DOI: 10.1111/resp.12930.
  21. Nurmagambetov, T., Kuwahara, R., & Garbe, P. (2018). The economic burden of asthma in the United States, 2008-2013. Annals of the American Thoracic Society, 15(3): 348-356. DOI: 10.1513/AnnalsATS.201703-259OC.
  22. O’Neill, S., Sweeney, J., Patterson, C. C., Menzies-Gow, A., Niven, R., Mansur, A. H., Bucknall, C., Chaudhuri, R., Thomson, N. C., Brightling, C. E., O’Neill, C., & Heaney, L. G. (2015). The cost of treating severe refractory asthma in the UK: An economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax, 70(4): 376-378. DOI: 10.1136/thoraxjnl-2013-204114.
  23. Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018). Asthma. The Lancet, 391(10122): 783-800. Lancet Publishing Group. DOI: 10.1016/S0140-6736(17)33311-1.
  24. Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., Frey, U., Gibson, P., Heaney, L. G., Holt, P. G., Humbert, M., Lloyd, C. M., Marks, G., Martinez, F. D., Sly, P. D., ... Bush, A. (2018). After asthma: redefining airways diseases. The Lancet, 391(10118): 350-400). Lancet Publishing Group. DOI: 10.1016/S0140-6736(17)30879-6.
  25. Pearson, K. (1900). On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science, 50(302): 157-175. DOI: 10.1080/14786440009463897.
  26. Princic, N., Burnette, A., Wang, Y., Pallavi, Rane, B., Chung, Y., Park, J., Llanos, J.-P., Lindsley, A. W., Christopher, & Ambrose, S. (2023). Incremental cost burden among patients with severe uncontrolled asthma in the United States. In JMCP.org (Vol. 29, Issue 7).
  27. Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L. P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., De Jongste, J. C., Kerstjens, H. A. M., Lazarus, S. C., Levy, M. L., O’Byrne, P. M., Partridge, M. R., Pavord, I. D., Sears, M. R., Sterk, P. J., ... Wenzel, S. E. (2009). An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations – Standardizing endpoints for clinical asthma trials and clinical practice. American Journal of Respiratory and Critical Care Medicine, 180(1): 59-99. DOI: 10.1164/rccm.200801-060ST.
  28. Settipane, R. A., Kreindler, J. L., Chung, Y., & Tkacz, J. (2019). Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Annals of Allergy, Asthma and Immunology, 123(6): 564-572. e3. DOI: 10.1016/j.anai.2019.08.462.
  29. Song, H. J., Blake, K. V., Wilson, D. L., Winterstein, A. G., & Park, H. (2020). Medical costs and productivity loss due to mild, moderate, and severe asthma in the United States. Journal of Asthma and Allergy, 13: 545-555. DOI: 10.2147/JAA.S272681.
  30. Sullivan, P. W., Slejko, J. F., Ghushchyan, V. H., Sucher, B., Globe, D. R., Lin, S. L., & Globe, G. (2014). The relationship between asthma, asthma control and economic outcomes in the United States. Journal of Asthma, 51(7): 769-778. DOI: 10.3109/02770903.2014.906607.
  31. Suruki, R. Y., Daugherty, J. B., Boudiaf, N., & Albers, F. C. (2017). The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulmonary Medicine, 17(1). DOI: 10.1186/s12890-017-0409-3.
  32. Van Ganse, E., Antonicelli, L., Zhang, Q., Laforest, L., Yin, D. D., Nocea, G., & Sazonov Kocevar, V. (2006). Asthma-related resource use and cost by GINA classification of severity in three European countries. Respiratory Medicine, 100(1): 140-147. DOI: 10.1016/j.rmed.2005.03.041.
  33. Vollmer, W. M., Markson, L. E., O’connor, E., Sanocki, L. L., Fitterman, L., Berger, M., & Buist, A. S. (1999). Association of Asthma Control with Health Care Utilization and Quality of Life. Am J Respir Crit Care Med (Vol. 160). -- www.atsjournals.org.
  34. Weiss, K. B., & Sullivan, S. D. (2001). The health economics of asthma and rhinitis. I. Assessing the economic impact. Journal of Allergy and Clinical Immunology, 107(1): 3-8. DOI: 10.1067/mai.2001.112262.
  35. Wilcoxon, F. (1945). Individual Comparisons by Ranking Methods. Biometrics Bulletin, 1(6): 83. DOI: 10.2307/3001968.
  36. Yousif, A., Dault, R., Courteau, M., Blais, L., Cloutier, A. M., Lacasse, A., & Vanasse, A. (2022). The validity of diagnostic algorithms to identify asthma patients in healthcare administrative databases: a systematic literature review. Journal of Asthma, 59(1): 152-168. DOI: 10.1080/02770903.2020.1827425.
  37. Zhang, S., White, J., Hunter, A. G., Hinds, D., Fowler, A., Gardiner, F., Slade, D., Murali, S., & Meeraus, W. (2023). Suboptimally controlled
  38. asthma in patients treated with inhaled ICS/LABA: prevalence, risk factors, and outcomes. Npj Primary Care Respiratory Medicine, 33(1).
  39. DOI: 10.1038/s41533-023-00336-9.

Metrics

Metrics Loading ...